Drug Trial Radar · NCT06235905
Open-Label of SPN-820 in Adults With Major Depressive Disorder
Last checked: Nov 19, 2026Latest source record: Oct 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Feb 15, 2024
Primary completion
Aug 18, 2024
Study completion Aug 18, 2024
Sponsor
- Lead sponsor
- Navitor Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Supernus Pharmaceuticals, Inc.
- First posted
- Feb 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate of the efficacy and safety of SPN-820 in Adults With Major Depressive Disorder (MDD)
Conditions
- Major Depressive Disorder
Interventions
NV-5138Drug
NV-5138 is a novel, orally bioavailable, mechanistic target of rapamycin complex 1 (mTORC1) signaling enhancer
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Each Time Point in the Hamilton Depression Rating Scale-6 Items (HAM-D6) Total Score (HAM-D6).Time frame: 10 days (end of study)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Viking Clinical Research
Temecula, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.